Overview
Ko Kudo practices in Hirosaki, Japan. Kudo is rated as an Advanced expert by MediFind in the treatment of Pure Red Cell Aplasia. Their top areas of expertise are Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, and Hereditary Neuroblastoma.
Their clinical research consists of co-authoring 41 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Pure Red Cell Aplasia.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- HistiocytosisKudo isDistinguished. Learn about Histiocytosis.
- Langerhans Cell HistiocytosisKudo isDistinguished. Learn about Langerhans Cell Histiocytosis.
- ReticulohistiocytomaKudo isDistinguished. Learn about Reticulohistiocytoma.
- Advanced
- Aase SyndromeKudo isAdvanced. Learn about Aase Syndrome.
- Acute Interstitial Pneumonia
- Hereditary Neuroblastoma
- Interstitial Lung Disease
- Leukemoid ReactionKudo isAdvanced. Learn about Leukemoid Reaction.
- Non-Langerhans-Cell Histiocytosis
- Experienced
- Achard SyndromeKudo isExperienced. Learn about Achard Syndrome.
- Acromicric DysplasiaKudo isExperienced. Learn about Acromicric Dysplasia.
- Acute Lymphoblastic Leukemia (ALL)
- Acute Megakaryoblastic Leukemia
- Acute Myeloid Leukemia (AML)
- Adrenal CancerKudo isExperienced. Learn about Adrenal Cancer.